【レポートの概要（一部）】
1. Report Overview
1.1 Biosimilars Overview
1.2 Biosimilars Market Segmentation
1.3 Why You Should Read this Report
1.4 How this Report Delivers
1.5 Main Questions Answered by this Report
1.6 Who is this Report for?
1.7 Research and Analysis Methods
1.8 Frequently Asked Questions (FAQ)
1.9 Some Associated Reports
1.10 About Visiongain
2. Introduction to Biosimilars and Biosimilar Drug Development
2.1 Biologics: Large, Complex Products which can be Very Effective, but also Very Expensive
2.2 Brief History of Biological Drug Development
2.3 What is a Biosimilar?
2.4 Brief History of Biosimilars
2.5 What are Interchangeable Biological Products and how Do They Differ from Biosimilars?
2.6 Prescription of Interchangeables vs Biosimilars and How This Sets the FDA Apart from the EMA
2.7 Main Segments of the Overall Biosimilars Market
3. The Global Biosimilars Market 2015-2025
3.1 The Global Biosimilars Market
3.2 Global Biosimilars Market Forecast 2015-2025
3.3 What Will Drive Growth in the Biosimilars Market?
3.3.1 Biosimilars Can Bring about Savings of Billions – $44bn for the US by 2024 and $33bn for Europe by 2020
3.3.2 Over $67bn worth of Biologic Patents due to Expire by 2020
3.3.3 US Approves First Biosimilar – Zarxio. Will this Open the Floodgates? Interchangeability Can also Drive Growth
3.3.4 Other Developed and Emerging Markets Will also Provide Opportunities for Growth
3.3.5 Competitive Landscape Emerging for Biosimilars
3.4 What Factors can Restrain Sales Growth in the Biosimilars Market?
3.4.1 Complexity of Biologics Means that Biosimilar Development Faces Many Challenges
3.4.2 Opposition from Originator Companies and Patent Issues
3.4.3 Fragmentation in the Market as Many Companies Chase the Same Targets
3.4.4 The Threat of Biobetters and Next-Generation Biologics
3.5 Summary of Drivers and Restraints for the Global Biosimilars Market
3.6 Biosimilar Market Forecast by Segment, 2015-2025
3.7 Leading Segments in the Biosimilars Market, 2014
3.8 Biosimilars as a Share of the Biologics Market, 2014
3.8.1 Outlook for the Overall Biologics Market
3.8.2 Seven Biologics Account for 31.8% of Total Market Revenue
4. Outlook for Biosimilars in Leading Developed Markets, 2015-2025
4.1 Regional Forecasts for the Global Biosimilars Market, 2015-2025
4.2 The US Biosimilars Market Outlook, 2015-2025
4.2.1 Current Status of the US Market
4.2.2 FDA Finalises Three New Guidelines on 351(k) Applications in April 2015
4.2.2.1 The History of the US’ Biosimilar Guidelines
4.2.3 Individual States Can Pass their Own Biosimilar Substitution Laws
4.2.4 US Biosimilars Market Forecast, 2015-2025
4.3 The European Biosimilar Market: History and Current Status
4.3.1 History of EMA Guidelines and Updates 2012-2014
4.3.2 Biosimilar Uptake in Europe Varies between Nations
4.3.3 European Biosimilars Market Forecast, 2015-2025
4.3.4 Inflectra and Remsima in Europe – Demonstrates a Path for Other Biosimilar MAbs
4.3.5 German Biosimilar Market Outlook, 2015
4.3.5.1 German Biosimilar Market Forecast, 2015-2025
4.3.6 French Biosimilars Market Outlook, 2015
4.3.6.1 Biosimilar Substitution Law Likely to Come into Effect in 2015
4.3.6.2 French Biosimilar Market Forecast, 2015-2025
4.3.7 UK Biosimilar Market Outlook, 2015
4.3.7.1 UK Biosimilar Market Forecast, 2015-2025
4.3.8 Italian Biosimilars Market Outlook, 2015
4.3.8.1 Italian Biosimilars Market Forecast, 2015-2025
4.3.9 Spanish Biosimilars Market Outlook, 2015
4.3.9.1 Spanish Biosimilar Market Forecast, 2015-2025
4.3.10 Biosimilar Regulation in Japan and Currently Approved Biosimilars
4.3.10.1 Differences between the European and Japanese Guidelines
4.3.10.2 Currently Approved Biosimilars in Japan
4.3.10.3 Japanese Biosimilar Market Forecast, 2015-2025
5. Outlook for Biosimilars in Emerging Markets, 2015-2025
5.1 China and India Lead Biosimilar Revenues
5.2 Biosimilar Growth in Emerging National Markets, 2015-2025
5.3 Chinese Biosimilars Market Outlook, 2015
5.3.1 China Publishes Final Guidelines for Biosimilars
5.3.2 Biosimilars Account for less than Half of Biotech Revenues in China
5.3.3 Chinese Biosimilars Market Forecast, 2015-2025
5.4 Indian Biosimilars Market Outlook, 2015
5.4.1 CDSCO Guidelines Released in 2012
5.4.2 Indian Biosimilars Market Forecast, 2015-2025
5.5 South Korea’s Established Biosimilar Guidelines
5.5.1 Currently Approved Biosimilars in South Korea, 2015
5.5.2 South Korean Biosimilars Market Forecast, 2015-2025
5.6 Russian Biosimilars Market Outlook and Forecast, 2015-2025
5.7 Brazilian Biosimilar Regulation
5.7.1 Government Eager to Promote Biosimilar Development, and Two Major Conglomerates, Bionovis and Orygen, are Racing to Produce Biosimilars
5.7.2 Brazilian Biosimilars Market Forecast, 2015-2025
6. Biosimilar Monoclonal Antibodies and Fusion Proteins: Submarket Forecast and Pipeline, 2015-2025
6.1 Monoclonal Antibodies (mAbs): The Largest Biologics Market Sector, Individual Drugs Accumulating Multi-Billion Dollar Revenues
6.2 Biosimilar MAbs and FPs Market Forecast, 2015-2025
6.3 Drivers for the Biosimilar MAbs and FPs Market
6.3.1 New Launches of Biosimilar MAbs and FPs in Developed and Emerging Markets
6.3.2 Rising Incidence of Cancer will Drive Demand
6.3.3 The Need for Lower Cost Therapies
6.3.4 Partnering to Launch Biosimilar MAbs
6.4 Restraints for the Biosimilar MAbs and FPs Market
6.4.1 Novel MAb Developers Choosing to Develop Biobetters and Next-Generation Therapies in Face of Biosimilar Competition
6.4.1.1 Hope for Biosimilars when Competing Against Next-Generation Therapies
6.4.2 Challenges in Antibody Development and Manufacturing
6.4.3 Patent Issues, Market Fragmentation and Perception of Biosimilars
6.5 Leading Targets for Biosimilar Development, 2015-2025
6.6 Biosimilar Rituximab
6.6.1 Approved Biosimilars
6.6.1.1 Reditux (Dr. Reddy’s Laboratories)
6.6.1.2 MabTas (Intas Pharmaceutical)
6.6.1.3 AcellBia (Biocad)
6.6.1.4 Kikuzubam (PROBIOMED) – Challenges
6.6.2 Biosimilar Rituximab Pipeline, 2015-2025
6.6.2.1 Terminated Developments
6.6.2.2 GP2013 (Sandoz)
6.6.2.3 BI 695500 (Boehringer Ingelheim)
6.6.2.4 MabionCD20 (Mabion)
6.6.2.5 CT-P10 (Celltrion)
6.6.2.6 PF-05280586 (Pfizer)
6.6.3 Biosimilar Rituximab Outlook, 2015-2025
6.7 Biosimilar Infliximab
6.7.1 Approved Biosimilars
6.7.1.1 Inflectra and Remsima (Hospira and Celltrion)
6.7.1.2 Inflimab and BOW015 (Epirus Biopharmaceuticals and Ranbaxy Laboratories)
6.7.2 Biosimilar Infliximab Pipeline, 2015-2025
6.7.2.1 NI-071 (Nichi-Iko)
6.7.2.2 ABP 710 (Amgen) and BX2922 (BioXpress Therapeutics)
6.7.3 Biosimilar Infliximab Outlook, 2015-2025
6.8 Biosimilar Trastuzumab
6.8.1 Approved Biosimilars
6.8.1.1 Hertraz and CanMab (Mylan and Biocon)
6.8.1.2 Herzuma (Celltrion)
6.8.2 Biosimilar Trastuzumab Pipeline, 2015-2025
6.8.2.1 BCD-022 (Biocad)
6.8.2.2 ABP 980 (Amgen and Actavis)
6.8.2.3 PF-05280014 (Pfizer)
6.8.3 Biosimilar Trastuzumab Outlook, 2015-2025
6.9 Biosimilar Adalimumab
6.9.1 Humira – The World’s Leading Antibody Therapy
6.9.2 Exemptia (Zydus Cadila)
6.9.3 Biosimilar Adalimumab R&D Pipeline, 2015-2025
6.9.3.1 ABP 501 (Amgen and Actavis)
6.9.3.2 GP2017 (Sandoz)
6.9.3.3 BI 695501 (Boehringer Ingelheim)
6.9.4 Biosimilar Adalimumab Outlook, 2015-2025
6.10 Biosimilar Etanercept
6.10.1 Enbrel is the Leading Fusion Protein
6.10.2 Enbrel Granted Extended Patent Protection in the US until 2029
6.10.3 Biosimilars are Available in Emerging Markets
6.10.3.1 Yisaipu (Shanghai CP Guojian Pharmaceutical) and Qiangke (Shanghai Celgen Biopharmaceutical)
6.10.3.2 Etacept (Cipla) and Intacept (Intas Pharmaceuticals)
6.10.3.3 Davictrel and HD-203 (Hanwha Chemical)
6.10.4 Biosimilar Etanercept Pipeline, 2015-2025
6.10.4.1 GP2015 (Sandoz)
6.10.4.2 CHS-0214 (Coherus Biosciences and Baxter)
6.10.5 Biosimilar Etanercept Outlook, 2015-2025
6.11 Avastin: Patents Not Set to Expire until 2019 in the US and 2022 in Europe
6.11.1 Biosimilar Bevacizumab Pipeline, 2015-2025
6.11.1.1 BCD-021 (Biocad)
6.11.1.2 ABP 215 (Amgen)
7. Biosimilar Insulin Submarket Outlook, 2015-2025
7.1 Insulin as Part of the Biological Drug Sector, 2015
7.2 30 Million People Expected to be Diagnosed with Diabetes by 2030
7.3 Approved Insulin Biosimilars
7.4 Abasaglar and Insulin Glargine BS – The First Insulin Biosimilars to be Approved in Developed Markets
7.5 EMA Releases Finalised Insulin Biosimilars Guideline
7.6 Tentative Approval for Basaglar in the US, but Launch Delayed until Mid-2016
7.7 Biosimilar Insulin Forecast, 2015-2025
7.8 Drivers for the Biosimilar Insulin Market, 2015-2025
7.9 Restraints for the Biosimilar Insulin Market, 2015-2025
7.10 Biosimilar Human Insulin Submarket, 2015-2025
7.10.1 A Submarket Mostly Restricted to Emerging Markets?
7.10.2 Biosimilar Human Insulin in China
7.10.3 Biosimilar Human Insulin in India
7.10.3.1 Wockhardt and Biocon – Given up on their Desire to Target the US and Europe?
7.10.4 Biosimilar Human Insulin Outlook, 2015-2025
7.11 Biosimilar Insulin Analogues
7.11.1 Available Biologic Insulin Analogues – Sanofi’s Lantus Tops Revenues
7.11.2 Insulin Glargine is the Main Biosimilar Target
7.11.2.1 Limited Development for the Other Targets
7.11.3 Insulin Market Leaders are Developing Ultra-Rapid Acting Insulin Analogues
7.11.3.1 Ultra-Long Acting Insulin also in Development
7.11.4 Mylan Partners with Biocon for Insulin Analogues
7.11.5 Biosimilar Insulin Analogue Outlook, 2015-2025
7.12 Biosimilar Insulin Glargine
7.12.1 Two Biosimilars are Available in India
7.12.2 Biosimilar Insulin Glargine Pipeline, 2015-2025
7.12.2.1 MK-1293 (Merck & Co. and Samsung BioLogics)
7.12.2.2 Mylan’s Insulin Glargine (Mylan)
7.12.3 Biosimilar Insulin Glargine Outlook, 2015-2025
7.13 Biosimilar Insulin Lispro
7.13.1 One Biosimilar Currently Available – Prandilin
7.13.2 Small Pipeline for the Future
7.13.3 Ultra-Rapid Acting Insulin: New Options
8. Biosimilar Erythropoietins Submarket Outlook, 2015-2025
8.1 Three Products Lead the Biologic EPO Therapy Market
8.2 Safety Concerns for Erythropoietin-Stimulating Agents
8.3 The Challenge from Oral Therapies is Coming
8.4 Treating Anaemia in Patients with CKD – the Leading Use of EPO Therapies
8.5 Biosimilar Epoetin Approvals in Europe
8.6 Epoetin Alfa Pipeline for the European Market, 2015
8.7 Trends in Uptake for Biosimilar Epoetins in Europe
8.8 Epoetin Alfa Pipeline for the US – Companies Preparing for Launch
8.9 Biosimilar Epoetin in Japan
8.10 Biosimilar Epoetin in South Korea
8.11 Biosimilar Epoetin in India and China
8.12 Second-Generation EPO Biosimilars
8.13 No Mircera Biosimilars in Clinical Development
8.14 Biosimilar EPO Market Forecast, 2015-2025
9. Biosimilar G-CSF Submarket Outlook, 2015-2025
9.1 Biologic Market Outlook: Amgen Leads the Biologic G-CSF Market
9.2 Teva Launches Long-Acting Pegfilgrastim
9.3 Selected Filgrastim Biosimilars Approved Worldwide
9.3.1 The European G-CSF Biosimilars Market
9.3.2 Tevagrastim (Teva): The First Biosimilar in Europe, Launched as Granix in the US
9.3.3 Nivestim (Hospira)
9.3.4 Zarzio (Sandoz): The Most Prescribed Biosimilar Therapy in Europe
9.3.4.1 Zarxio Becomes the First Biosimilar in the US
9.3.5 Multiple Launches in Japan 2013-2014
9.3.6 Biosimilar Filgrastim and Pegfilgrastim in India
9.3.6.1 Biosimilars in Russia and Other Emerging Markets
9.4 Biosimilar G-CSF Market Forecast, 2015-2025
9.4.1 Drivers and Restraints for the Biosimilar G-CSF Market
9.4.2 Trends in Biosimilar Uptake Across Europe
10. Biosimilar Interferons Submarket Outlook, 2015-2025
10.1 Competition for the Multiple Sclerosis Market – Challenges for Interferon Beta Therapies
10.2 All-Oral Regimens will Challenge Interferon Alfa Therapy
10.2.1 However Oral Therapies Will be Expensive
10.3 Biologic Interferon Therapy Market Outlook
10.4 There Are No Approved Biosimilars in Developed Markets
10.5 Biosimilar Interferons Market Forecast, 2015-2025
10.6 Biosimilar Interferon Alfa
10.6.1 Biosimilar Interferon Alfa – a Common Target in Developing Countries, Leading to Fragmented Markets
10.6.2 Biosimilar Peginterferon Alfa
10.6.3 Hepatitis Treatment Rates are Low
10.6.4 Biosimilar Interferon Alfa Outlook, 2015-2025
10.7 Biosimilar Interferon Beta
10.7.1 Biosimilars are Well-Established in Emerging Markets
10.7.2 Biosimilar Interferon Beta Pipeline
10.7.3 EMA Guidance
10.7.4 Long-Acting Interferon Beta
10.7.5 Biosimilar Interferon Beta Outlook, 2015-2025
11. Biosimilar Recombinant Hormones Submarket Outlook, 2015-2025
11.1 Biologic Growth Hormone Market in 2014 – Novo Nordisk and Pfizer Dominate
11.1.1 Biologic Growth Hormone Market Outlook, 2015-2025
11.2 Biosimilar Growth Hormones
11.2.1 Omnitrope – Well Established in Developed Markets
11.2.2 Multiple Biosimilars Available Worldwide
11.2.3 Biosimilar Growth Hormones in Asia
11.2.4 Biosimilar Uptake Varies by Region
11.2.5 Biosimilar Growth Hormones Market Forecast, 2015-2025
11.3 Fertility Hormones
11.3.1 Two Products Lead the Biologic Fertility Hormone Market
11.3.2 Long-Acting Follicle Stimulating Hormone (FSH)
11.3.3 Biologic Fertility Hormones Market Outlook
11.3.4 Available Biosimilar Fertility Hormones
11.3.4.1 Ovaleap (Teva) and Bemfola (Finox) Approved in Europe
11.3.5 Rising Infertility to Drive Demand to 2025
11.3.6 Biosimilar Fertility Hormones Forecast, 2015-2025
12. Biosimilars: Qualitative Analysis and Industry Trends, 2015
12.1 SWOT Analysis of the Biosimilars Market
12.2 Biosimilars Market: Strengths
12.2.1 Biosimilars Can Offer Huge Cost Savings
12.2.2 The US Finally Joins the Global Biosimilars Market
12.2.3 Biosimilars are Already Well-Established in Many National Markets
12.2.4 Outsourcing Offers the Chance for Further Cost Savings
12.3 Biosimilars Market: Weaknesses
12.3.1 Biosimilars are High Cost to Develop and Manufacture
12.3.2 Complexity Means that Development Timelines are Long
12.3.3 Uptake for Biosimilars Varies and is Low in Some Regions
12.4 Biosimilars Market: Opportunities
12.4.1 Blockbuster Biologics Face Patent Expiry
12.4.2 Rising Disease Prevalence
12.4.3 Licensing Agreements for Biosimilars
12.5 Threats
12.5.1 Biobetters and Next-Generation Biologics
12.5.2 Patent Issues and Product Life Cycle Management from Originator Companies
12.5.3 Fragmentation in the Market
12.5.4 Long Market and Data Exclusivity Periods
12.5.5 Biosimilars Require Marketing and Education
13. Research Interviews from Our Survey
13.1 Interview with Sandra Sánchez y Oldenhage, MBA, Deputy CEO of PROBIOMED
13.1.1 Introduction to PROBIOMED
13.1.2 PROBIOMED’s Most Prominent Biosimilars and its Future Pipeline
13.1.3 Withdrawal of Kikuzubam and Changes in Mexican Biosimilar Regulation
13.1.4 On Standing out from the Competition
13.1.5 On How the Biosimilars Market will Develop over the Next Ten Years and its Main Strengths
13.2 Interview with Dr Ralph Warsinsky, Executive Director of Product Communications at Boehringer Ingelheim
13.2.1 On Boehringer Ingelheim’s Current Biosimilar Pipeline and its Reasons for Entering the Biosimilars Space
13.2.2 On Boehringer Ingelheim’s Track Record with Biopharmaceuticals and the Factors Needed to Become Successful in the Biosimilars Industry
13.2.3 Advantages over Competitors and Thoughts on the US Market
14. Conclusions from Visiongain’s Research and Analysis
14.1 Rapid Growth Expected for this High-Potential Market
14.2 Biosimilar Monoclonal Antibodies to be the Fastest Growing Segment
14.3 A Range of Factors Will Stimulate Demand
14.4 Challenges Remain in Developing and Successfully Launching Biosimilars
【レポート販売概要】
■ タイトル：バイオシミラーおよび後発生物製剤の世界市場：モノクローナル抗体、融合タンパク質、インスリン、エリスロポエチン、G-CSF、インターフェロン、ヒト成長ホルモン、生殖ホルモン■ 英文：Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2015-2025
■ 発行日：2015年6月
■ 調査会社：visiongain
■ 商品コード：VGAIN50612
■ 調査対象地域：グローバル
- Energie NB Power：発電所及びSWOT分析2013Energie NB Power - Power Plants and SWOT Analysis, 2013 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives), and major products and services. Scope - Major Power Plants (assets) - summarized and de …
- 哺乳瓶消毒器の世界市場2015-2019About baby bottles sterilizers The baby care products market is a sensitive market due to the emotional value attached to such products, including baby bottle sterilizers. Parents are always concerned about getting the best and safest products for their children. Thus, marketing strategies involve emotional appeal rather than logical and point-based appeals. Developing countries have witnessed rap …
- 補償光学の世界市場2017-2021ABSTRACTAbout Adaptive Optics Adaptive optics technology helps improve the performance of optical systems by decreasing the effect of wavefront distortions. The deformations in the incoming wavefront are corrected by adaptive optics by deforming a mirror to compensate the distortion. Adaptive optics technology is popular in astronomical telescopes and laser communication systems to negate the effe …
- ユニファイドコミュニケーションの世界市場分析：製品別（オンプレミス、、クラウドベース/ホスト）、用途別（企業、教育、行政、ヘルスケア）、セグメント予測The global unified communications market size is expected to reach USD 143.49 billion by 2024, according to a new report by Grand View Research, Inc. The substantial growth prospects of the unified communications market can be attributed to the rapid international expansion of organizations and an increasing need for real-time and efficient communication systems that enhance the inter-organization …
- The Williams Companies, Inc.：石油・ガスバリューチェーン分析レポート2013The Williams Companies, Inc. Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "The Williams Companies, Inc." Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “The Williams Companies, Inc.”. The report provides key information relating to oil and gas assets of the company along with its operations across the valu …
- 自動車用センサーモジュールの世界市場2016-2020About Global Sensor Module Market in the Automotive Sector A sensor module is made up of a sensor, cover, and wiring unit. The cover is used to hold the sensor in place and includes a connector to create a connection with the external device. The cover also holds the wiring unit, which is attached from the connector to the sensor. The cover is made of mold material. The wiring includes a second co …
- 世界の調味料、ドレッシング及びソース市場のM&A動向（2014年6月）Synopsis The report provides a review of the mergers and acquisitions (M&As), partnering deals, and agreements entered into by companies active in the global seasonings, dressings & sauces market during June 2014. Summary Using this report, dealmakers will effectively gain an insight into deal activity of the global seasonings, dressings & sauces market throughout the month. Additionally, the repo …
- 男性不妊治療の世界市場：DNA断片化、酸化ストレス分析、顕微鏡検査、精子侵入アッセイ、精子凝集、CASAAbout Male Infertility Infertility is a widespread problem. In male infertility, the male fails to impregnate his female partner after a year of unprotected sex. Male infertility is due to a couple of factors including: • Low sperm production • Abnormal sperm function or • Blockages that prevent the delivery of sperm. Hormonal disturbances to physical problems, or psychological problems can cause …
- 油田用空気掘削の世界市場：ほこり、気泡流体、フォーム、ミストGlobal Oilfield Air Drilling Market: About this market Air drilling is a technique where high volumes of low-pressure air are used to drill oil and gas wells instead of conventional drilling fluids such as water-based mud or oil-based mud especially in the areas with low or no influx of water inside the wellbore. Technavio’s oilfield air drilling market analysis considers sales from dust, aerated …
- スマートシティの世界市場：スマートセキュリティ、スマートインフラ、スマートエネルギー、スマートガバナンス、スマート教育、スマートビル、スマート医療、スマートモビリティAbout Smart City A smart city uses ICT, including mobile networks, to improve the quality of livelihood in a sustainable way. A smart city combines and shares disparate comprehensive data sets captured by intelligently-connected infrastructure, people, and vehicles, to generate new insights. It also provides ubiquitous services that enable citizens to access information about city administrative s …
- カラーマスターバッチの世界市場予測（～2021）The market size of color masterbatch is projected to reach USD 4.75 Billion by 2021, registering a CAGR of 5.6% between 2016 and 2021. The rapid growth in the packaging industry in Asia-Pacific is a key driver of the color masterbatch market. Packaging is the dominating industry in the market. It is widely used for industrial and household purposes. Improved lifestyle and globalization have trigge …
- 世界の数値流体力学（CFD）市場：CFDソフトウェア、CFDサービスAbout CFD To analyze the flow, turbulence, and pressure distribution of liquids and gases, and their interaction with structures, various end-users implement the CFD software. CFD is the science of predicting fluid flow, mass transfer, chemical reactions, and related phenomenon. To simulate the flow of fluids (gases and liquids), CFD uses high-speed computers, various numerical methods, and solver …
- 下垂体ACTH過剰分泌(クッシング病)：グローバル臨床試験レビュー（2014年上半期）Pituitary ACTH Hypersecretion (Cushing's Disease) Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Pituitary ACTH Hypersecretion (Cushing's Disease) Global Clinical Trials Review, H1, 2014" provides data on the Pituitary ACTH Hypersecretion (Cushing’s Disease) clinical trial scenario. This report provides elemental information and data relating to the clinical t …
- スマートフォンカバー用ガラス産業動向Despite a sea of changes in the touch sensor industry, the smartphone cover glass industry remained stable and prosperous in 2013. However, the booming market has also brought fierce competition among vendors in the industry. This report profiles the development of important vendors in 2013 and forecasts the industry's trends in 2014.
- 農業におけるフェロモンの世界市場予測（～2025年）The global pheromones market is projected to grow at a CAGR of 15.3% from 2019 to 2025. The global pheromones market size is estimated to be valued at USD 2.4 billion in 2019 and is projected to reach USD 5.7 billion by 2025, recording a CAGR of 15.3%. The growing adoption of organic agriculture and sustainable farming practices coupled with the increasing demand for high-value crops such as fruit …
